Antidepressants in Alzheimer's Disease: A Focus on the Role of Mirtazapine

被引:20
作者
Correia, Ana Salome [1 ,2 ]
Vale, Nuno [1 ,3 ]
机构
[1] Ctr Hlth Technol & Serv Res CINTESIS, OncoPharma Res Grp, Rua Doutor Placido da Costa, P-4200450 Porto, Portugal
[2] Univ Porto, Inst Biomed Sci Abel Salazar ICBAS, Rua Jorge Viterbo Ferreira 228, P-4050313 Porto, Portugal
[3] Univ Porto, Fac Med, Dept Community Med Hlth Informat & Decis MEDCIDS, Alameda Prof Hernani Monteiro, P-4200319 Porto, Portugal
关键词
Alzheimer's disease; depression; mirtazapine; MILD COGNITIVE IMPAIRMENT; SEROTONIN REUPTAKE INHIBITORS; OBSESSIVE-COMPULSIVE DISORDER; MAJOR DEPRESSIVE DISORDER; DOUBLE-BLIND; AMYLOID-BETA; OPEN-LABEL; SLEEP ARCHITECTURE; MOUSE MODEL; SERTRALINE;
D O I
10.3390/ph14090930
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Mirtazapine belongs to the category of antidepressants clinically used mainly in major depressive disorder but also used in obsessive-compulsive disorders, generalized anxiety, and sleep disturbances. This drug acts mainly by antagonizing the adrenergic alpha 2, and the serotonergic 5-HT2 and 5-HT3 receptors. Neuropsychiatric symptoms, such as depression and agitation, are strongly associated with Alzheimer's disease, reducing the life quality of these patients. Thus, it is crucial to control depression in Alzheimer's patients. For this purpose, drugs such as mirtazapine are important in the control of anxiety, agitation, and other depressive symptoms in these patients. Indeed, despite some contradictory studies, evidence supports the role of mirtazapine in this regard. In this review, we will focus on depression in Alzheimer's disease, highlighting the role of mirtazapine in this context.
引用
收藏
页数:15
相关论文
共 115 条
  • [1] Depression in Alzheimer's Disease: A Delphi Consensus on Etiology, Risk Factors, and Clinical Management
    Aguera-Ortiz, Luis
    Garcia-Ramos, Rocio
    Grandas Perez, Francisco J.
    Lopez-Alvarez, Jorge
    Montes Rodriguez, Jose Manuel
    Olazaran Rodriguez, F. Javier
    Olivera Pueyo, Javier
    Pelegrin Valero, Carmelo
    Porta-Etessam, Jesus
    [J]. FRONTIERS IN PSYCHIATRY, 2021, 12
  • [2] Al-Majed A, 2018, PROF DRUG SUB EXCIP, V43, P209, DOI 10.1016/bs.podrm.2018.01.002
  • [3] Alam A., 2013, PRIM CARE COMPANION, V15, DOI [10.4088/PCC.13r01525, DOI 10.4088/PCC.13R01525]
  • [4] An Open-Label Study of Mirtazapine as Treatment for Combat-Related PTSD
    Alderman, Christopher P.
    Condon, John T.
    Gilbert, Andrew L.
    [J]. ANNALS OF PHARMACOTHERAPY, 2009, 43 (7-8) : 1220 - 1226
  • [5] Is serotonin an upper or a downer? The evolution of the serotonergic system and its role in depression and the antidepressant response
    Andrews, Paul W.
    Bharwani, Aadil
    Lee, Kyuwon R.
    Fox, Molly
    Thomson, J. Anderson, Jr.
    [J]. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2015, 51 : 164 - 188
  • [6] Effects of mirtazapine in patients with post-traumatic stress disorder in Korea: a pilot study
    Bahk, WM
    Pae, CU
    Tsoh, J
    Chae, JH
    Jun, TY
    Chul-Lee
    Kim, KS
    [J]. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2002, 17 (07) : 341 - 344
  • [7] Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial
    Banerjee, Sube
    Hellier, Jennifer
    Dewey, Michael
    Romeo, Renee
    Ballard, Clive
    Baldwin, Robert
    Bentham, Peter
    Fox, Chris
    Holmes, Clive
    Katona, Cornelius
    Knapp, Martin
    Lawton, Claire
    Lindesay, James
    Livingston, Gill
    McCrae, Niall
    Moniz-Cook, Esme
    Murray, Joanna
    Nurock, Shirley
    Orrell, Martin
    O'Brien, John
    Poppe, Michaela
    Thomas, Alan
    Walwyn, Rebecca
    Wilson, Kenneth
    Burns, Alistair
    [J]. LANCET, 2011, 378 (9789) : 403 - 411
  • [8] Barkin R L, 2000, Am J Ther, V7, P205, DOI 10.1097/00045391-200007030-00008
  • [9] Impact of SSRI Therapy on Risk of Conversion From Mild Cognitive Impairment to Alzheimer's Dementia in Individuals With Previous Depression
    Bartels, Claudia
    Wagner, Michael
    Wolfsgruber, Steffen
    Ehrenreich, Hannelore
    Schneider, Anja
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2018, 175 (03) : 232 - 241
  • [10] Mirtazapine orally disintegrating tablet versus sertraline:: A prospective onset of action study
    Behnke, K
    Sogaard, J
    Martin, S
    Bäuml, J
    Ravindran, AV
    Ågren, H
    Vester-Blokland, ED
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (04) : 358 - 364